Epilepsy is a common neurological disorder involving recurrent seizures and affecting about 1% of the population worldwide. Despite several antiepileptic drugs and effective therapies available for epilepsy, about 25% of the patients show therapeutic failure. Thus there exists an unmet need for newer antiepileptic drugs targeting newer targets with different mechanisms of action. Current research in epilepsy generally focuses on mechanisms that control neuronal excitability. Recently attention has been focussed on novel targets, their various interactions, and signalling cascades relating to epilepsy. This review summarizes several experimental and clinical findings from literature and explores potential targets which may play crucial role in epilepsy.
Introduction
Epilepsy is an important neurological disorder which has been reported in literature since 3000 years. It has been found to affect about 1% of population worldwide and has profoundly affected many aspects of quality of life [1, 2] . The incidences of epilepsy are currently seen more in the developing countries than the developed countries and it affects people of all races, ages and social groups [3] . Rural population of the developing countries is more affected than the urban population [3] . Epilepsy is primarily a disorder characterised by spontaneously occurring seizures that involves hyperexcitable neurons [1, 4] . It is well-known that in epilepsy, there is an imbalance between GABA-mediated and glutamate mediated neurotransmission [1] . Epileptic seizures occur due to abnormal, excessive electrical discharges which may be localized or widely distributed. Several factors are responsible for occurrence of seizures which may include genetic predisposition, a physiological or chemical stimuli capable of precipitating seizure, an underlying central nervous lesion or a combination of these factors [5, 6] .
Despite of several antiepileptic drugs available for epilepsy, around 30% of epileptic patients i.e. about 15 million people in the world, show therapeutic failure [7, 8] . Thus their exists an unmet need for newer antiepileptic drugs targeting newer targets with different mechanisms of action. Current research in epilepsy generally focuses on mechanisms that control neuronal excitability. Recently attention has been focussed on novel targets, their various interactions, and signalling cascades relating to epilepsy. [9, 10] .
This review summarizes several experimental and clinical findings from literature and explores potential targets which may play crucial role in epilepsy. From various experimental and clinical observations it is evident that brain inflammation is an important factor in epilepsy [11] . Thus several inflammatory targets like Interlukin-1b (IL-1b), Transforming Growth Factor b (TGF-b) and their role along with inhibition strategy are explained in this review. Since mammalian target of rapamycin (mTOR) plays a key role in multiple mechanisms of epileptogenesis [12] this target and its inhibition strategies are also mentioned in our review. Likewise several targets like P-glycoprotein (Pgp), mutations in voltage gated ion channels like Hyperpolarization-activated cyclic nucleotide-gated channels (HCN) and Kv7 or (M-) channels, Na-K-2Cl cotransporter (NKCC1) and their involvement in epilepsy is discussed.
Outline of mechanisms involved in pathogenesis of epilepsy
The primary mechanisms by which the currently available antiepileptic drugs eliminate seizures are gamma-aminobutyric Abbreviations: IL-1B, interlukins 1-beta; LPS, lipopolysaccharide; ICE, IL-1b converting enzyme; TLE, temporal lobe epilepsy; BBB, blood brain barrier; NMDA, N-methyl-D-aspartate; IL-1R1, interlukin-1 receptor, type 1; TNF-alpha, tumor necrosis factor-alpha; PTZ, pentylenetetrazole; Pgp, P glycoprotein; COX-2, cyclooxygenase-2; HCN, hyperpolarization activated cyclic nucleotide gated ion channel; GABA, gamma-aminobutyric acid; Nfr2, nuclear factor -E2 related factor; NKCC1, Na-K-2Cl cotransporter; KCC2, K-Cl cotransporter; Trkb, tropomyosinreceptor-kinase B; BDNF, brain-derived neurotrophic factor; TGF-Beta, transforming growth factor beta; mTOR, mammalian target of rapamycin; TSC, tuberous sclerosis complex.acid (GABA), glutamate receptors and neuronal ion channels [13] . Recently, anti-inflammatory effects of antiepileptic drugs have gained attention [14] . For example, currently available antiepileptic drugs like carbamazepine and levetiracetam were found to exhibit anti-inflammatory effects, i.e. they reduced the expression of inflammatory mediators in glial cell cultures [14, 15] . Levetiracetam was also able to normalize the resting membrane potential of astrocytes which was elevated by inflammatory mediators [14] . According to literature, it is also known that the disruption of blood-brain barrier (BBB) is responsible for increased abnormal neuronal firing [13] . Leukocyte invasion into brain as well as leakage of serum protein occurs due to the disruption of the BBB [13] . Seizure thresholds are lowered by these exogenous inflammatory mediators [16] . Thus, brain inflammation may promote epileptogenesis and hence we have discussed certain inflammatory mediators as potential targets for treatment of epilepsy.
Despite of several antiepileptic drugs available, the problem of pharmacoresistance still persists [17] . Thus there is a need to understand the pathomechanisms giving rise to pharmacoresistance [17] . Genetic mutations causing dysfunctioning of voltage gated ion channels contribute to different types of familial epilepsy [18] . Voltage gated channels control the excitability of normal cells by regulating their membrane potential, firing rate and synaptic transmission [19] . Functional changes occurring in these ion channels due to mutations causes hyperexcitability of neurons, leading to seizures [19] .
Oxidative stress is involved in the progression of epilepsy and studies have shown that it is an underlying mechanism for progression of epilepsy, particularly induced by kainic acid and pilocarpine [20] . Mitochondrial superoxide radical mediated oxidative stress was suggested to play a role in excitotoxicity induced by kainic acid seizures and it was also suggested that antioxidants may prove beneficial in the treatment of seizures [21] . Two cation-chloride cotransporters have been discussed as potential targets in epilepsy as they can control the reverse potential of GABAA-receptor mediated current [22] . Similarly other targets like purinergic receptors which are ligand-gated ion channels are discussed as potential targets, as their activation by ATP contributes to glio-and neuro-transmission [23] .
The potential targets for epilepsy based on the above mentioned mechanisms are discussed briefly as follows.
Targets related to inflammation
3.1. Interlukin-1b (IL-1b) role in epilepsy and its modulation to minimize seizures Experimental seizures have led to induction of inflammatory processes in brain regions in which epileptic activity originates and spreads [13] . It has been observed that in rodent brain during seizures, synthesize and release IL-1b in astrocytes and microglia [24] . Within 30 min of seizure onset, astrocytes and microglia produce elevated cytokine levels. As a result of this, the wave of inflammation spreads to endothelial cells of BBB involving clusters of neurons in those areas in which seizures originate and spread [25] . In addition to elevation of IL-1b which occurs due to seizures, it can also modulate susceptibility to seizure inducing stimuli [26] . Thus activation of IL-1b receptor signalling in glia and neurons contributes to intrinsic brain inflammation [27] . Activation of this signalling further exacerbates seizures induced by kainic acid and bicuculine in rats and mice [26, 28] . It is reported from previous studies that IL-1b converting enzyme (ICE, caspase 1) plays a key role in converting IL-1b in its active form and that the genetic deletion of ICE has prevented negative physiological responses to lipopolysaccharide (LPS) induced inflammation [29] . It has been reported from the previous studies that release of IL-1b is reduced due to inhibition of ICE/caspase-1 in organotypic hippocampal slices following exposure to proinflammatory stimuli [30] . Thus from above evidences it can be hypothesized that inhibitors of ICE/ caspase-1 may prove beneficial in epilepsy and they can be investigated further. Previous studies have also reported a mechanistic link between proconvulsant effects of IL-1b and NMDA receptors [31] . It has been seen that enhanced Ca 2+ influx is mediated by N-methyl-D-aspartate (NMDA) which occurs by Interlukin-1 receptor, type 1 (IL-1R1) dependent activation of Src kinases and neuronal sphingomyelinases which causes phosphorylation of NR2B subunit of NMDA receptors [31, 32] . Also it has been seen that NMDA receptors having NR2B subunit are main targets for glutamate released from activated astrocytes, thus leading to induction of slow inward currents of neurons [31] . These slow inwards currents act as excitatory events. These currents are increased in animal models of epilepsy and can trigger action potentials in neurons due to their role in neuronal synchronization [33] . Thus these currents may act as an important molecular event by which IL-1b worsens seizures [34, 35, 36] . Also it has been reported from previous studies that IL-1b inhibits reuptake of glutamate from astrocytes and may lead to increased release of glutamate via tumor necrosis factor (TNF-a) from glia, ultimately promoting hyperexcitability [36, 37] . The exact mechanism by which these proinflammatory cytokines like IL-1b and TNF-a inhibits reuptake of glutamate is unknown, but previous study reports from murine models and human fetal astrocyte cultures using nitric oxide synthase inhibitors have suggested that nitric oxide is involved in the suppression of glutamate uptake activity by IL-1b as IL-1b stimulated human astrocytes generate substantial amounts of nitric oxide [38, 39, 40] . Also studies carried out by Bezzi et al, [41] have suggested the involvement of TNF-a in releasing glutamate, where they had proposed a signaling cascade mechanism for glutamate exocytosis from astrocytes via TNF-a. From the results it was proposed that stromal cell-derived factor 1 (SDF-Ia) stimulates CXCR4-dependent signaling in astrocytes as well as microglia and contributes synergistically to release TNF-a with activation of tumor necrosis factor receptor 1 (TNFR1) in astrocytes and potentiate downstream signaling, causing glutamate release [41] . Thus inhibition of IL-1b may be beneficial strategy to minimize epilepsy.
Inhibition of IL-1b as an approach to treat epilepsy
Previous experimental studies by Maroso et al, [42] have reported the beneficial effect of VX-765 (a selective ICE/caspase-1 inhibitor) in epilepsy [42] . It was observed that in kainic acid induced seizures in C57BL-6 mice, VX-765 showed potent anticonvulsant effect by its inhibition of IL-1b via inhibition of ICE/caspase-1 and modulation of NMDA receptors [42] . Another recent experimental study by Carlos et al, [43] investigated the role of vinpocetine in pentylenetetrazole (PTZ) and 4-aminopyridine model of epilepsy. From the study it was proved that vinpocetine caused reduction of IL-1b expression in rat hippocampus. Based on this study, it was proposed that vinpocetine through its cerebral anti-inflammatory effect may also contribute to the anti-seizure action [43] . Thus targeting IL-1b inhibition by several approaches and signaling pathways like ICE/caspase-1 and NMDA receptor modulation discussed above may prove beneficial in epilepsy.
Modulators of transforming growth factor beta (TGF-b)
Recent studies have shown the involvement of TGF-b pathway in epilepsy. It has been demonstrated previously by Cachaeux et al. [44] that disruption of blood-brain barrier leads to the development of focal epileptiform activity and albumin is critical in this process of epileptogenesis [44] . Albumin interacts with TGF-b receptors in astrocytes and causes activation of TGF-b signaling pathway by Smad 2 phosphorylation thus leading to early dysfunctioning of astrocytes and seizures [44] . It has been observed that TGF-b blockers minimize these transcriptional changes induced by albumin and prevents generation of epileptiform activity. Thus targeting TGF-b receptors may prove to be a beneficial strategy.
Inhibition of TGF-b as an approach to treat epilepsy
Klein and co-workers in their experimental studies [45] have tested the effect of losartan in epilepsy by blocking albumin induced TGF-b pathway activation in rat models of vascular injury [45] . Thus inhibition of TGF-b pathway may prove beneficial in epilepsy. Pirfenidone known for its anti-fibrotic actions is known to inhibit TGF-b directly as per the studies by Mathew at. al. in renal cells [46, 47] . Fluorofenodine, a novel pyridine agent was recently studied in angiotensin II stimulated model of renal cells and significantly reduced TGF-b pathway expression [48] . Thus based upon all recent findings these drugs could be investigated further in epilepsy due to their ability to inhibit TGF-b.
Targeting P-glycoprotein (Pgp) upregulation in epilepsy
It has been seen that upto 8-40% of epileptic patients show resistance to antiepileptic medications [49] . Previous studies from animal models have shown the correlation between Pgp and epilepsy [50] . Pgp is highly expressed in capillary endothelial cells of the blood-brain barrier and it is also known to transport a wide range of substrates across the blood brain barrier [50] . Also, increased Pgp expression is seen in limbic brain region of mice and rats model of temporal lobe epilepsy (TLE) as well as in resected brain tissue of patients with refractory TLE undergoing epilepsy surgery [51, 52] . The exact cause of drug resistance in epilepsy is still not understood. One theory of occurrence of drug resistance in epilepsy is that the mRNA levels of Pgp gene, i.e ABCB1, is upregulated in the BBB of drug resistant epileptic patients [53] . Pgp limits a large number of drugs from crossing the BBB [54] . Thus upregulation of Pgp at BBB prevents antiepileptic drugs from entering the brain and causes drug resistance in epilepsy [55, 56, 57] . Also, recent in-vivo data has demonstrated that Pgp limits antiepileptic drugs from penetrating the brain [58] . It was shown by Loescher and Potschka [51, 58] that Pgp expression at the BBB was increased in animals not responding to phenytoin and phenobarbital as compared to those responding to the treatment [58] . Recent studies also reported that Pgp is increased due to glutamate release during seizures, which occurs via N-methyl-Daspartate (NMDA) receptor and cyclo-oxygenase-2 (COX-2) [59, 60] . Therefore targeting Pgp via NMDA receptor and COX-2 may prove beneficial in drug resistant epilepsy.
Inhibition of Pgp as an approach in pharmacoresistant epilepsy

Direct Pgp inhibition
Pgp function was first found to be inhibited by Ca 2+ -channel blocker verapamil and hence it has been used to tackle drug resistance epilepsy [61, 62] . According to a few clinical case reports, patients not responding to various combination treatments of drug showed significant reduction of seizures when verapamil was coadministered with antiepileptic drugs [63, 64] . Previous studies have reported that verapamil was used in patients with refractory epilepsy and showed effects by inhibiting Pgp [65, 66] . In addition, indomethacin a non selective COX inhibitor was found to inhibit Pgp elevation in animal models of epilepsy [59, 60] . Thus direct inhibition of Pgp may prove as a beneficial approach in resistant epileptic patients. Cyclosporin A and tamoxifen are some of the drugs inhibiting Pgp which could be investigated further [62, 67] .
However Cyclosporin A leads to hepatotoxicity and nephrotoxicity which limits its use [68] . Also biricodar and annamycin are second and third generation Pgp inhibitors which could also be investigated further for epilepsy as these drugs were tested in clinical trials where they inhibited Pgp mediated efflux and were successful in reversing the resistance in cancer patients [67, 69] . According to previous studies, biricodar was found to cause myelosuppression in women being treated for metastatic breast cancer. However myelosuppression was not for prolonged period of time [70] .
4.1.2. Pgp inhibition via modulation of NMDA receptor and COX-2 As discussed previously increased Pgp expression occurs due to release of glutamate via NMDA and COX-2 receptors. Zhu et al, [71] had shown that glutamate signalled Pgp elevation was decreased in cultured brain capillary endothelial cells by blocking NMDA receptor with NMDA antagonist like dizocilpine (MK-801) [71] . Patel et al, [72] had demonstrated the correlation between COX-2 mediated inflammation and Pgp and that COX-2 activation leads to the increase in Pgp expression [72] . This ultimately leads to the hypothesis that Pgp is elevated in epilepsy via the involvement of COX-2 in glutamate/NMDA receptor pathway. Therefore targeting this pathway could prove as beneficial strategy in pharmacoresistant epilepsy. Data obtained from previous experimental studies showed that celecoxib, a selective COX-2 inhibitor, blocked upregulation of Pgp mediated via glutamate in isolated rat brain capillaries, whereas no such significant effect was observed in case of COX-1 inhibitor [73] . Other highly selective COX-2 inhibitors, SC-58236 and NS-398, have been reported to counteract status epilepticus associated elevation in Pgp expression in the ventral hippocampus and parahippocampal cortex [74] . Thus, based upon these findings this pathway could be investigated further for pharmacoresistant epilepsy.
Modulation of hyperpolarization-activated cyclic nucleotidegated channel (HCN) and Kv7 voltage gated ion channels
Both HCN and Kv7 channels are voltage gated ion channels. HCN channels are widely expressed in hippocampus, cortex, and thalamus regions of the brain which are responsible for the generation of focal and generalised seizures [75] . Kv7 channels also contribute to neuronal hyperexcitability [76] . As compared to Kv7 channels the role of HCN channels in epilepsy is slightly complex. It has been observed from previous studies that genetic deletion of HCN1 channel subtype accelerates epileptogenesis whereas genetic deletion of HCN2 channel subtype causes absence epilepsy phenotype [75] . It has also been observed that blocking of HCN channel produces neuronal hyperexcitability. Fewer studies have also examined the role of HCN1 deletion for evidence of epilepsy [77, 78] . These studies had demonstrated that HCN1 deletion increased the severity of seizures induced by kindling or chemoconvulsants along with high death rate from status epilepticus [77, 78] . Also alterations have been seen in HCN current, I h and HCN levels due to seizures in animal models of temporal lobe epilepsy as well as in cortical tissues of temporal lobe epilepsy patients [79] . Previous studies had also reported that in kainic acid induced model of seizures, significant reduction in I h and HCN protein levels was seen in entorhinal cortex within first 24 h of seizures [80] . Currently available antiepileptic drugs like lamotrigine and gabapentin also have action on HCN channels [75] . Thus HCN channels may also serve as beneficial target in epilepsy. From experimental studies done by Lan Cheng et al. [81] it was seen that niflumic acid a non-steroidal anti-inflammatory drug modifies the gating of HCN2 pacemaker channels. The drug also enhances the effect of gamma-aminobutyric acid (GABA) and acts as Cl-channel blocker [81] . Thus the drug can be investigated further in epilepsy.
Similarly many mutations in Kv7/KCNQ genes are also associated with epilepsy [82] . Also it has been observed from previous studies that mice lacking Kv7 subunits, as well as those in which mutated Kv7.2 subunits were knocked off, became epileptic [83] . Kv7 channel opener retigabine has been proven as an effective anticonvulsant in several animal models of epilepsy [84, 85] . It acts by activating voltage-gated potassium channels and therefore decrease neuronal excitability [85] . From previous studies it has been observed that Kv7 channels supress repetitive firing of action potentials [86] . However, retigabine was withdrawn from clinical use due to side effects such as blue discolouration of the skin and eye abnormalities. Thus, more studies using other Kv7 channel opener are required to prove efficacy and safety of this category of drugs. Nevertheless, Kv7 channel is a potential target and needed to be explored more.
Modulators of nuclear related factor 2 (Nrf2)
This target focuses on oxidative stress related mechanisms of epilepsy. It has been seen from recent studies that Nrf2-ARE signaling pathway serves as an important target in protecting the brain from the damage caused by ischemic stroke [87] and kainate toxicity [88] . From studies by Mazzuferi et al, [89] elevated mRNA expression of Nrf2 was observed in hippocampal tissues of patients with temporal lobe epilepsy [89] . Similarly Nrf2 genes like HO-1 and NQO1 were also elevated [89] . Wang et al, [90] had also evaluated Nrf2-ARE signaling pathway activation in seizuremediated damage and cognitive impairment induced by epileptic seizures [90] . Sulforaphane was used to activate the pathway and the treatment had reduced the after discharge duration and had also ameliorated cognitive impairment induced by epileptic seizures [90] . In this study, significant elevation in HO-1 and NQO-1 genes was observed [90] . Thus, from above experimental findings it can be hypothesized that the activation of Nrf2-ARE signaling pathway increases the expression of antioxidant enzymes (HO-1, NQO-1) and supresses epileptic seizures. Wang et al, [91] had also evaluated the activation of Nrf2-ARE signaling pathway and its genes (HO-1, NQO-1) after seizures [91] . From their study it was concluded that seizures induce oxidative stress in the hippocampus of epileptic rats thus activating Nrf2-ARE pathway and ultimately leading to elevation of antioxidant enzymes which may decrease oxidative damage [91] . Thus from all above findings it can be hypothesized that activation of Nrf2-ARE pathway may prove as a beneficial strategy.
Activation of Nrf2-ARE pathway as an approach to treat epilepsy
As discussed previously, sulforaphane treatment by activating Nrf2-ARE pathway was found to decrease seizures. Studies by Thornalley et al, [92] had shown the beneficial effect of semisynthetic triterpenoid bardoloxone methyl in chronic renal failure by direct activation of Nrf2-ARE pathway [92] . Further, in vitro studies have shown the effect of magnesium lithospermate B against high glucose induced oxidative stress via Nrf2 activation [93] . Luo et al, [92] had first demonstrated the effect of MG132, which is a proteasome inhibitor in diabetic nephropathy via Nrf2 activation [94] . Thus based upon previous findings, above mentioned compounds can be investigated further for epilepsy via Nrf2-ARE pathway activation.
Modulators of Na-K-2Cl cotransporter (NKCC1) and K-Cl cotransporter (KCC2)
Earlier studies reported that altered expression of chloride transporters like (KCC2/NKCC1) induces excitatory GABA actions and ultimately contributes to generation of seizures in temporal lobe epilepsy [95] . Due to decreased levels of intracellular chloride [Cl-]i GABA causes membrane hyperpolarization in mature neurons of adults [95] . Further, immature neurons of neonates increase intracellular [Cl-]i, thereby causing GABA to trigger efflux of chloride and membrane depolarization [96] . Na-K-2Cl cotransporter (NKCC1) and K-Cl cotransporter (KCC2) plays an important role in controlling neuronal [Cl-]i, wherein the former promotes depolarizing GABA response whereas the latter promotes hyperpolarizing GABA response [97] . In epilepsy and trauma, imbalance in NKCC1 and KCC2 activity may indicate the change from hyperpolarizing to depolarizing effect and vice versa effect of GABA [98] . Thus NKCC1 and KCC2 transporters should be considered as an important target for epilepsy [98] . It was reported that Tropomyosin-receptor-kinase B (TrkB) receptor of brain-derived neurotropic factor (BDNF) plays an important role in epileptogenesis [99] . Eftekhari et al, [95] had shown that BDNF by modifying hippocampal KCC2 and NKCC1 expression delayed the occurrence of spontaneous recurrent seizures and had also ameliorated the hyperexcitability behaviour in pilocarpine model of status epilepticus [95] . From this study it was observed that NKCC1 expression was upregulated, whereas KCC2 expression was downregulated in hippocampus of epileptic rats [95] . So treatment with single high dose and multiple injections of BDNF increased KCC2 expression and decreased NKCC1 expression with only single high dose of BDNF [95] . Another example is of bumetanide, which according to recent studies has been found to inhibit epileptic activity in various in-vivo and in-vitro models of neonatal seizures by its ability to specifically inhibit NKCC1 at low doses and ultimately switch the GABA equilibrium potential of immature neurons from depolarizing to hyperpolarizing [100] .
Inhibition of NKCC1 and activation of KCC2 as an approach to treat epilepsy
Recent studies suggest that increased [Cl] i of immature neurons of neonates is due to NKCC1 activity and it has been proposed that inhibition of NKCC1 reduces [Cl] i which may ultimately reduce GABA-mediated enhanced excitation of immature neurons and could even convert GABA response to inhibitory [100] . Thus inhibition of NKCC1 and activation of KCC2 may prove as beneficial strategy to treat epilepsy and these targets can also be further investigated for treatment of neonatal seizures. According to very recent data, experimental studies are being conducted to develop newer derivatives of bumetanide having the potential to inhibit NKCC1 and ultimately inhibit epilepsy by using Xenopus oocyte heterogenous system for comparing effects in human splice variants like hNKCC1A and hNKCC2A [101] . Furosemide is also reported to inhibit NKCC1 activity [102] . Therefore developing furosemide derivatives may also prove as a beneficial strategy to treat epilepsy.
Modulation of purinergic receptors
It is found that ATP activates P2X receptors which are ligand gated ion channels and this activation leads to neuro and glio transmission [103] . During seizures, concentration of K + is increased in the extracellular space. In response to this change, Panx1 channels present in hippocampal neurons and astrocytes are opened and ATP is released. Activation of ATP receptors leads to the hyperactivity of neurons, ultimately leading to progression of seizures [104] . In comparison to ATP, it is seen that adenosine exhibits an antiepileptic activity via P1A1 receptor. Activation of this purinergic receptor inhibits the release of glutamate from presynaptic endings [105] . After status epilepticus, many of the receptors of P2X family like P2 Â 2, P2 Â 4 and P2 Â 7 in the hippocampus are found to be altered [103] . Down-regulation of P2 Â 2 receptor has been observed after status epilepticus [106] alongwith decreased expression of P2 Â 2 receptor in seizuresensitive gerbils [107] . P2 Â 4 knockout mice have shown reduction in death occurring after status epilepticus, although no alteration in seizures were seen in these mice [108] , along with decreased inflammatory signaling with no change in IL-1b levels [103, 108] . Recent data suggests that mice lacking P2 Â 7 receptor activity show altered seizures in response to chemoconvulsants thus suggesting the beneficial role of P2 Â 7 receptor ligands on seizure severity during status epilepticus [103] . It is also seen that after prolonged seizures P2 Â 7 receptor expression is elevated in the damaged regions of neurons and glia [104] . Antagonists of P2 Â 7 receptor have showed anticonvulsant activity in animal models of status epilepticus. For e.g. injection of P2 Â 7 receptor antagonists BBG or A-438079 have led to reduction of seizures during status epilepticus induced by microinjection of kainic acid in amygdala of mice [106] . It is also observed that mice showing deficiency of P2 Â 4 receptors decreases neuronal death occuring after status epilepticus. Thus P2X receptors may prove as beneficial targets in epilepsy.
Modulation of mammalian target of rapamycin (mTOR) pathway
The mTOR signalling pathway is found to play a role in multiple functions, some of which have direct role to play in neuronal excitability and epileptogenesis [109] . Several clinical and preclinical studies have revealed that mTOR signalling pathway is involved in genetic and acquired epilepsy syndromes, as well as other forms of epilepsy [109] . Hyperactivation of mTOR signalling is seen in epilepsy and thus it can be explored as a beneficial target for treatment of epilepsy [109] . mTOR pathway has been recently examined in animal models of medial temporal lobe epilepsy [110] . It has been seen that in kainic acid and pilocarpine model of status epilepticus, S6, a downstream molecule in mTOR pathway becomes phosphorylated [9] . Treatment with mTOR inhibitor rapamycin was found to reduce seizure frequency [111] . Data from preliminary clinical trials have suggested that mTOR inhibitors minimize seizures in tuberous sclerosis complex (TSC) patients with intractable epilepsy [112] . mTOR pathway is also found to modulate the expression of glutamate receptors [113] . Also recent data has suggested that abnormal neuronal signaling occurs due to involvement of mTOR in mechanisms of synaptic structure and plasticity [114] . Thus mTOR inhibitors can prove to be antiepileptic due to their ability to block neuronal excitability by acting on ligand and voltage gated channels, signaling pathways and neurotransmitter receptors [115] .
Inhibition of mTOR pathway as an approach to treat seizures
A number of experimental studies have evaluated the effect of mTOR inhibitor Rapamycin in kainic acid models as well as other models of status epilepticus [116] . mTOR inhibitors exert neuroprotective effects by reducing mossy fiber sprouting in animal models of status epilepticus [9] . The role of mossy fiber sprouting in epileptogenesis is unclear, but it is a common neuropathological finding in patients with temporal lobe epilepsy [117] . However, it has been observed that sprouted mossy fibers form recurrent, excitatory connections [118] . Also from hippocampal slice experiments, it has been observed that after mossy fiber sprouting, granule cells monosynaptically excite one another and result in seizure-like events [119] . Data obtained from experimental studies have suggested the possible mechanism by which focal and systemic treatment of rapamycin inhibits mTOR signaling pathway and suppresses mossy fiber sprouting in rats [117] . Evidences suggests that mTOR signaling pathway plays an important role in mossy fiber sprouting. Also it has been observed that traumatic brain injury and status epilepticus activate the mTOR signaling pathway [120] . Activation of mTOR signaling pathway stimulates the growth of axons in hippocampal and cultured sensory neurons [121] . Also it has been observed that with excessive mTOR activity mossy fiber sprouting develops in transgenic animals without prior epileptogenic injury [122] . mTOR inhibitor rapamycin suppresses regeneration of axon and guidance of growth cones [123] . As discussed previously, mTOR inhibitors are still under clinical trials for treatment of epilepsy. In a very recently conducted randomized controlled trial, Sirolimus was evaluated in children with TSC and had reduced the seizure frequency. Larger trials or meta analysis are being carried out to evaluate the complete efficacy of the drug [124] . Thus several drugs inhibiting mTOR pathway could be investigated further in epilepsy. Also repurposing of old drugs inhibiting mTOR pathway could be investigated further in epilepsy.
Aberrant neurogenesis involved in epilepsy
In almost all the mammalian species, hippocampal dentate granule cells are generated continuously [125] . Generation of these new neurons is disrupted during the development of epilepsy [125] . Neurogenesis is increased after epileptogenesis [126] . It has also been observed that epileptic seizures lead to aberrant hippocampal neurogenesis which include production of ectopic granule cells, increased proliferation of neural progenitors, mossy fiber sprouting and neuronal hypertrophy [127, 128] . From previous studies it was suggested that inhibiting adult hippocampal neurogenesis by using certain nonspecific pharmacological agents after acute seizures leads to reduction of seizures [129] . Also from studies by Cho et al. [127] , it was seen that spontaneous recurrent seizures were minimized by blocking adult neurogenesis [127] . Seizure frequency was minimized even at chronic stage of disease by single ablation of adult neurogenesis, thus suggesting the important role of aberrant neurogenesis in epileptogenesis process [127] . According to recent studies, aspirin was found to inhibit aberrant neurogenesis in pilocarpine induced status epilepticus in rats and it had minimized spontaneous recurrent seizures [130] . Thus blocking of aberrant neurogenesis may prove beneficial in epilepsy.
Conclusion
Despite of several antiepileptic drugs available to treat seizures, around 30% of epileptic patients show failure of therapy. This suggests the need to find newer antiepileptic drugs with novel targets. In this review, we have explored some of the targets having beneficial role in epilepsy which can be investigated further. Since brain inflammation occurs in epilepsy, the potential role of inflammatory targets like IL-1b, TGF-b in epilepsy is discussed along with inhibition strategies of these targets that may prove beneficial. Since mTOR pathway is involved in epileptogenesis process by multiple mechanisms, inhibition of mTOR pathway could prove beneficial in epilepsy. Pharmacoresistance to currently available antiepileptic drugs is seen in some of the patients. Therefore strategies to inhibit Pgp upregulation are discussed in this review. Likewise, mutations in voltage gated ion channels like HCN and Kv7 channels have led to seizures. Hence modulation of these channels may play a beneficial role. Based upon previous experimental studies and their findings we have concluded that the modulation of targets mentioned here may prove beneficial in epilepsy and can be investigated further.
Development of all drugs proposed in this review with potential to modulate a particular target might be impractical. Hence, in our opinion, developing a drug like niflumic acid, which can modulate HCN channel (a voltage gated channel) might be a better option. Also as discussed previously, niflumic acid enhances the effect of GABA. Therefore it may prove promising for treatment of epilepsy. mTOR inhibitors are under clinical trials for epilepsy. mTOR is also involved in process of epileptogenesis and its inhibitors have been proven to have anti-seizure action. Therefore, repurposing of drugs having potential to inhibit mTOR might prove to be a viable option in epilepsy. Another potential approach can be adjuvant therapy of verapamil with anti-seizure drugs in patients with refractory epilepsy, which has been proven effective in recent studies.
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